July 22, 2022

CHAIN announces the appointment of Dr Matthew Duchars as Chief Executive from the 1st of August 2022 Nottingham, UK- 22nd of July 2022- FOR IMMEDIATE RELEASE CHAIN Biotechnology has strengthened its senior management team through the appointment of Dr Matthew Duchars. Matthew is an experienced leader in vaccine development and manufacture with senior management roles […]

June 22, 2022

CHAIN announces a new collaboration with clinical researchers at the University of Oxford to develop superior oral vaccines for infectious diseases Marlow, UK- 22nd of June 2022- FOR IMMEDIATE RELEASE CHAIN Biotechnology and the University of Oxford plan to collaborate on a two-year project to develop a new type of vaccine to immunise against human […]

May 31, 2022

Following successful patent applications in the EU and US, CHAIN have extended their patent territories and claimed delivery of β-hydroxy butyrate (β-HB) to the gastrointestinal (GI) tract in Japan. The patent family (publication number: WO2018055388) ‘Compositions and uses thereof for treating inflammatory diseases and probiotic compositions’ covers genetically engineered bacterial strains to express β-HB in […]

May 7, 2021

 CHAIN has developed a platform technology called CADDTM for oral drug delivery based on living bacteria (known as live biotherapeutics).  CADDTM is unique, transformational with broad clinical applicability. US and EU patents describing the use of CADDTM to treat inflammatory bowel disease have recently been granted. Marlow, UK – 7th May 2021 – FOR IMMEDIATE […]

January 4, 2021

Oxford Vacmedix and CHAIN Biotech have signed Heads of Terms for a Collaboration Agreement to develop and commercialise oral vaccines targeting cancer & infectious disease Marlow, UK – 4th January 2021 – FOR IMMEDIATE RELEASE CHAIN Biotechnology (CHAIN), a UK-based microbiome therapeutics company, focused on the development of oral vaccines, announced today that Heads of […]

June 22, 2020

Following a 2-month closure, CHAIN reopened its laboratories in Nottingham on the 1st June. This comes after a risk assessment and change to working practices to maintain safe working for staff in the labs and office. MediCity has also implemented new measures in the building to support safe working practices which have also contributed to […]

May 11, 2020

An Oxford based nutritional company, TdeltaS Ltd (TΔS®), has developed and commercialised a proprietary ketone ester, which can be used as a food to improve human physical performance and cognitive function in health and disease.  The Company’s product, ΔG®, is a ketone monoester that is marketed by HVMN Inc. in the USA for use in their sports […]

April 20, 2020

CHAIN is pleased to announce a new 18-month research collaboration with Associate Professor John Heap and his research group at the University of Nottingham.     Dr Heap is Associate Professor of Synthetic Biology in the School of Life Sciences at the University of Nottingham, where he is also part of the newly-formed Biodiscovery Institute […]

April 2, 2020

Andrew has had a distinguished career at Danisco/DuPont, acting as Chief Scientific Officer (2008–2011) for Danisco and Chief Scientist for DuPont Nutrition & Health (2011–2019).  He was appointed a DuPont Fellow in 2016 and played a key role in helping build DuPont’s microbiome platform.      Having retired from DuPont at the end of 2019, […]

November 5, 2019

”An expansive view of design has been adopted at CHAIN Biotechnology, which is developing new therapeutics based on living microbes where the “bug is the drug.” These drugs are based on a single strain of Clostridium bacteria that is naturally found in the gut, but which has been deliberately engineered to carry a therapeutic payload, such as […]